Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s Pevonedistat Misses Primary Goal in PIII for MDS, MML, AML
September 3, 2021
- Astellas Pauses AT132 Gene Therapy Trial after Serious Adverse Event
September 2, 2021
- Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
September 2, 2021
- Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
- MSD Urges Govt to Start HPV Vaccine Discussions as Soon as Possible
September 2, 2021
- SymBio, Singapore’s National Cancer Centre Tie Up to Investigate Brincidofovir’s Anti-Tumor Activity
September 2, 2021
- Former Novartis Japan Chair Masao Torii Tapped as Fronteo’s Strategic Advisor
September 2, 2021
- NanoCarrier’s Otitis Media Treatment Smashes Primary Endpoints in Japan PIII
September 2, 2021
- Kyowa Kirin Files Automated-Injection Device of G-Lasta in Japan
September 2, 2021
- Acetaminophen Prescribed to Over 3 Million Patients in July due Possibly to COVID-19 Vaccine Reactions: Survey
September 1, 2021
- Sawai’s Rising Shipment Controls Now Hit 420 Products
September 1, 2021
- Lilly, Daiichi Sankyo Tie Up on Another Migraine Drug in Japan
August 31, 2021
- Lixiana Hits Goal in High-Risk AF Patients after Heart Valve Procedure
August 31, 2021
- Alnylam’s 2nd siRNA Therapy Givlaari Hits Japan Market
August 31, 2021
- Santen Files Diquas Follow-Up for Dry Eye in Japan
August 31, 2021
- Otsuka Launches Migraine Drug Ajovy in Japan
August 31, 2021
- Tagrisso Filed in Japan for Adjuvant Therapy in EGFR NSCLC
August 31, 2021
- Active Investments in Biotech Upstarts Needed to Create Healthcare Ecosystems: Shonan iPark Manager
August 30, 2021
- Medical Societies Issue Joint Statement in Face of Possible Stockout of Abraxane, Calling for Continued Treatment
August 30, 2021
- Nippon Shinyaku Aims to Maximize Value of Viltepso, Double Sales, Operating Profits in 10 Years: President
August 27, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…